Adrenal News

In a review of the 2024 milestones, Healio | Endocrine Today compiled a list of drugs and devices related to the field that were newly approved, cleared or had label or indication changes. Information was gathered from the FDA website and news releases. We put our best effort into making a complete list and regret any omission. Appearance of a drug or device does not constitute any endorsement by Healio | Endocrine Today, its editors, publishers or editorial board. — The Editors

Among patients with endogenous hypercortisolism, relacorilant improved cardiometabolic parameters such as blood pressure, HbA1c and weight, according to results of a long-term extension study.

Adults diagnosed with endogenous Cushing’s syndrome have a higher risk for developing cancer compared with controls without the condition, according to data published in the European Journal of Endocrinology.

Adults with primary aldosteronism had improvements in disease severity after undergoing an adrenalectomy, according to findings published in Endocrine Practice.

The FDA has granted priority review designation for two new drug applications for a selective corticotropin-releasing factor type 1 receptor to treat congenital adrenal hyperplasia, according to a press release.

ORLANDO — Nearly one-quarter of adults with difficult-to-control type 2 diabetes also have hypercortisolism, and treating hypercortisolism may also benefit glycemic control in those with both conditions, according to speakers.

PHILADELPHIA — Adults with Cushing’s syndrome who responded to relacorilant had sustained improvements in blood pressure and glucose levels through 34 weeks, according to findings from a phase 3 trial.

BOSTON — In this video exclusive, Maria Fleseriu, MD, FACE, discusses some of the top adrenal and pituitary news from ENDO 2024.

BOSTON —In this video exclusive, Richard J. Auchus, MD, PhD, describes a possible new treatment paradigm for congenital adrenal hyperplasia with crinecerfont, an investigational drug granted a breakthrough designation in December.